 Atazanavir was marketed in 2003 and is an azapeptide protease inhibitor designed to fit the C2-symmetry of the enzyme binding site.Atazanavir showed better resistant profiles than previous HIV protease inhibitors.It is unique among the other protease inhibitors as it can only be absorbed in an acidic environment.